Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

91.6K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
91.6K
Genomics02:02

Genomics

36.5K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
36.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.

Nature communications·2026
Same author

Genome Sequencing Enhances Precision and Clinical Utility of Pharmacogenetic Data Compared to Arrays.

Journal of clinical pharmacology·2026
Same author

Neurofilament Light Chain: A Potential Biomarker for Chemotherapy-Induced Peripheral Neuropathy in Adolescent Young Adults.

Journal of adolescent and young adult oncology·2026
Same author

Reduction of next-generation sequencing files for efficient pharmacogenotype extraction.

Pharmacogenomics·2026
Same author

The 2023 clinical laboratory genetics workforce in the United States: trends, challenges, and evolving practices.

Human genetics·2026
Same author

Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171.

Cancer·2026

Related Experiment Video

Updated: Jul 23, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.8K

Computational pharmacogenotype extraction from clinical next-generation sequencing.

Tyler Shugg1, Reynold C Ly2, Wilberforce Osei1

  • 1Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.

Frontiers in Oncology
|July 20, 2023
PubMed
Summary
This summary is machine-generated.

The Aldy computational method accurately extracts pharmacogenomic (PGx) genotypes from clinical whole genome sequencing (WGS) and whole exome sequencing (WES) data. This supports repurposing NGS data for personalized medicine and clinical PGx applications.

Keywords:
next-generating sequencingpharmacogenetic algorithmpharmacogenetics (PGx)pharmacogenomics (PGx)whole exome sequencing (WES)whole genome sequencing (WGS)

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.2K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.0K

Related Experiment Videos

Last Updated: Jul 23, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.8K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.2K
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA

Published on: August 21, 2016

13.0K

Area of Science:

  • Genomic Medicine
  • Computational Biology
  • Clinical Pharmacology

Background:

  • Next-generation sequencing (NGS) is increasingly used in clinical care.
  • Repurposing NGS data for clinical pharmacogenomics (PGx) requires validated computational methods.
  • Current computational approaches for PGx from NGS data lack extensive clinical validation.

Purpose of the Study:

  • To assess the accuracy of the Aldy computational method for extracting PGx genotypes from clinical WGS and WES data.
  • To validate Aldy's performance against a CLIA-certified PGx genotyping reference standard.
  • To determine the utility of Aldy in identifying clinically actionable PGx variants from NGS data.

Main Methods:

  • Germline DNA from 264 patients was analyzed using panel-based genotyping and clinical WGS/WES.
  • Aldy versions 3.3 and 4.4 were employed to extract PGx genotypes from NGS data.
  • Aldy-derived genotypes were compared to a reference standard comprising 45 star allele-defining variants in 14 major pharmacogenes.

Main Results:

  • Aldy v3.3 achieved >99% concordance with genotyping for WGS data, identifying additional actionable alleles.
  • Aldy v4.4 demonstrated >99% concordance for WGS and WES data, with high accuracy even with variations like CYP2D6 copy number.
  • Mean read depth for WGS and WES data exceeded 30x, ensuring reliable genotype calling.

Conclusions:

  • Aldy v3.3 and v4.4 accurately call pharmacogene diplotypes from clinical WGS and WES data with >99% accuracy.
  • These findings validate Aldy's capability to repurpose clinical NGS data for informing clinical PGx decisions.
  • The study supports the integration of Aldy into clinical workflows for enhanced personalized medicine.